

# CURRICULUM VITAE

## PERSONAL DATA

**Jai Min Ryu, M.D., PhD**

Associate Professor

Breast Division, Department of Surgery

Sungkyunkwan University School of Medicine

Samsung Comprehensive Cancer Center, Samsung Medical Center

50 Ilwon-Dong, Gangnam-Gu, Seoul, 06351, South Korea

Office: 82-2-3410-3479, Fax: 82-23410-6982

Email: sheol1981@naver.com/jaimin.ryu@samsung.com

Orcid id: 0000-0001-5405-7385



## ACADEMIC APPOINTMENTS

2023.3-present Associate Professor

Sungkyunkwan University School of Medicine

Division of Breast Surgery, Department of General Surgery

Samsung Comprehensive Cancer Center, Samsung Medical Center

2022.3-2023.2 Associate Professor

2020.3-2022.2 Assistant Professor

2018.3-2020.2 Clinical Assistant Professor

Division of Breast Surgery, Department of General Surgery

Samsung Comprehensive Cancer Center, Samsung Medical Center

## POSTDOCTORAL TRAINING

2015.5-2018.2 Clinical Fellow

Division of Breast Surgery, Department of General Surgery

Samsung Comprehensive Cancer Center, Samsung Medical Center

2012.3-2015.4 Military Service

2008.3-2012.2 Resident

Department of General Surgery, Samsung Medical Center

Samsung Comprehensive Cancer Center, Samsung Medical Center

2007.3-2008.2 Intern

Yeungnam University Hospital

## EDUCATION

2017.3~2019.8	Ph.D. in Medicine	Sungkyunkwan University School of Medicine
2010.3-2016.8	Master of Science	Sungkyunkwan University School of Medicine
2001.3-2007.2	Medical Doctor	Yeungnam University School of Medicine

## THESES

2016.8	Master of Science (Mentor: Prof. Seok Jin Nam) “Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy.”
2019.8	Ph.D. in Medicine (Mentor: Prof. Jeong Eon Lee) “ <i>BRCA1/2</i> mutation in triple negative breast cancer in Korea”

## LICENSURE and CERTIFICATION:

2007	Registered Physician
2012	South Korean Board of Surgery
2015	Korean Hereditary Breast Cancer Counsellor
2016	Breast Sugery specialists

## MILITARY SERVICE:

2012.2-2014.4	Medical company commander, 1 <sup>st</sup> division of Military Army Surgeon, Republic of Korea
2014.5-2015.4	Forensic doctor, Minister of National Defense

## HONORS and AWARDS:

**April 2021 Young Investigator Award**, “Robot-assisted Nipple-sparing Mastectomy With Immediate Breast Reconstruction: Initial experiences of Korea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG)”, 10th Global Breast Cancer Conference

**March 2019 Global Poster Presentation**, “Prediction of Axillary Pathologic Response with Breast Pathologic Complete Response after Neoadjuvant Chemotherapy”, Society of Surgical Oncology 2019

**February 2019 Best Oral Presentation award**, “Prediction of Axillary Pathologic Response with Breast Pathologic Complete Response after Neoadjuvant Chemotherapy”, Seoul International Symposium of Surgical Oncology 2018

**April 2018 Young Investigator Award**, “Only estrogen receptor "Positive" is not enough to predict

the prognosis of breast cancer Running head: Revisiting estrogen positive tumors in 8th AJCC staging era”, Global Breast Cancer Conference 2018

**February 2018 Best Oral Presentation award**, “Only estrogen receptor "Positive" is not enough to predict the prognosis of breast cancer Running head: Revisiting estrogen positive tumors in 8th AJCC staging era”, Seoul International Symposium of Surgical Oncology 2018

**May 2017 Young investigator award**, The effect of Subtype on Mortality in Young Breast Cancer according to age, The 69<sup>th</sup> Korean Surgical Society Conference.

**Nov 2016 Best investigator award**, Re-classification of the BRCA1 C.5339T>C (p.L1780P) variant based on clinical evidence, The 68th Korean Surgical Society Conference.

## **EDITORIAL BOARDS**

2021- Editorial Member, Journal of Breast Disease

## **CLINICAL TRIAL EXPERIENCE**

2025.10 A comparative study to evaluate targeting methods for axillary surgery in patients with clinically node-positive breast cancer (LUCAS): A prospective multicenter pilot study (NCT06903429, KBCSG36) (as a co-investigator)

2024.08 Evaluation of Different methods of Targeting axillary lymph node for axillary surgery in patients with clinically node-positive breast cancer : A retrospective multicenter study (DITTO study) **(as a PI)**

2023.12 Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS). A multicenter randomized phase III trial. (as a co-investigator)

2023.10 Methods for Localization of Different Types of Breast Lesions (MELODY): A prospective non-interventional multicenter cohort study to evaluate different imaging-guided methods for localization of malignant breast lesions **(as a National PI)**

2023.05 Study to evaluate the prevalence of BRCA1/2 mutation with clinicopathological parameters in unselected female breast cancer patients with low estrogen receptor positive/HER2 negative, multicenter, retrospective study

- 2023.04- Development prediction model for late recurrence in young women (LADY) (from the National Research & Development Program for Cancer Control through the National Cancer Center funded by the Ministry of Health & Welfare, HA23C014400) (as a PI)
- 2022.09- A Prospective Multicenter Randomized Clinical Trial: Robot-assisted vs. Open nipple-sparing Mastectomy with Immediate Breast Reconstruction (ROM) trial (KoREa-BSG 05) (NCT05490433, KCT0007592) (as a co-investigator)
- 2021.09- Long term follow-up of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRAII study (HC19C0147) (as a co-investigator)
- 2022.05- Omission of breast surgery for Predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy (OPTIMIST) (NCT05505357, KCT0007638, HA22C009800)
- 2021.09- Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy (ASLAN) Trial (NCT04993625, KCT0006371, NTO1213151) (as a co-investigator)
- 2021.03- Analysis of circulating tumor DNA (ctDNA) in lung, breast and colorectal cancer patients for early cancer diagnosis (NTX1220491) (as a co-investigator)
- 2020.05- Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer (NCT04214210, KCT0005643, Korea-Swiss Innovation Program, 2019K1A3A1A1406308014)
- 2020.04- Prospective Cohort Study of Mastectomy with Reconstruction including Robot Endoscopic Breast Surgery (MARRES) (KoREa-BSG03, KBCSG-23) (KCT0006150, NCT04585074, PHO0215021)
- 2020.11- Validation of clinical treatment score post five-years (CTS5) in breast cancer patient for Predicting late distant recurrence (Funded by Korea Breast Cancer Foundation, PHO0204131) (as a PI)
- 2020.03- No Axillary surgical Treatment In clinically Lymph node negative patients after

- UltraSonography (NAUTILUS): A Prospective, Multicenter, phase III Clinical Trial (KBCSG-21)(NCT04303715, HC19C0110) (as a co-investigator)
- 2020.03- A randomized controlled trial for doing vs. Omitting intraoperative Frozen section biopsy For resection MArgin status in selected Patients undergoing breast conserving surgery (OFF-MAP) (KBCSG-17) (NCT03975179) (as a co-investigator)
- 2020.03- A retrospective study of identification of clinico-pathological features of breast cancer patients who recurred after achieving pCR with neoadjuvant chemotherapy followed by surgery (KBCSG-18) (as a co-investigator)
- 2020.02 A Multicenter, Randomized, Open-label, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark inj. Versus Charcotrace inj. in Patients with Nonpalpable Breast Lesions (as a co-investigator) (NCT04606329, CRIS: KCT0006123)
- 2019.01-2021.01 Prediction of Response for Neoadjuvant Chemotherapy using GenesWell™ BCT score in patients with Hormonal Receptor positive / HER-2 negative breast cancer (SMO1190121) (as a PI)
- 2018.01-2019.06 A Single-center, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark inj. (Conc. for fluorescence) Localization in Patients with Nonpalpable Breast Lesions (NCT03743259, CRIS: KCT0003798) (as a co-investigator)
- 2017.06-2018.10 Single-center, non-randomized, retrospective, single-arm investigator trial, Study to evaluate the prevalence of BRCA 1 / 2 mutation and prognosis factor with clinicopathological parameters in unselected female breast cancer patients with triple negative breast cancer. (as a co-investigator)
- 2017.05-2020.02 Single-center, non-randomized, retrospective, single-arm investigator trial, Clinical performance study of breast cancer prognostic diagnostics GenesWell™ BCT in Korean patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer (HI17C1142) (as a co-investigator)
- 2017.1- POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsive BC, IBCSG 48-14 / BIG 8-13) (as a co-investigator)
- 2017.02- Reference material development for PARP inhibitor companion diagnostics development and analytical validation (PHO0170551) (as a co-investigator)
- 2016.12- Single-center, non-randomized, retrospective, single-arm investigator trial, Study to evaluate

comparative Analysis and correlation to between GenesWell™ BCT and prognosis factor with clinicopathological and molecular genetic parameters from Hormone receptor positive(ER+ and/or PR+), human epithelial receptor 2 negative(HER2-) and early breast carcinoma female patients (PHO0170391) (as a co-investigator)

2016.06-2019.4 Comparative Medicine based Development of Breast cancer detection Kit for Human and Dogs (NTO1190471) (as a co-investigator)

2016.09- Optimal concentration of indocyanine green in near-infrared fluorescence guided sentinel lymph node biopsy in breast cancer (as a co-investigator)

2016.06-2020.10 Single-center, randomized, prospective, double arm trial, Suppression of inflammation by using NSAIDs during immediate post-operative period can affect the prognosis of breast cancer (as a co-investigator)

2013.04- Prospective Cohort Study for Development of Personalized Treatment Strategy Based on Biologic Tumor Behavior and Clinical Characteristics in Young Breast Cancer (YBC) Patients (as a co-investigator)

2015.12- Single-cell level genome study to discover biomarkers and to overcome treatment resistance for breast cancer patients (as a co-investigator)

## **SCIENTIFIC SOCIETY**

2025-present Deputy Secretary General, Organizing committee of Global Breast Cancer Conference (GBCC) 2024-2025

2025-present Deputy Secretary General of Korean Breast Cancer Society (KBCS)

2023-2025 Assistant Secretary General, Organizing committee of Global Breast Cancer Conference (GBCC) 2024-2025

2023-2025 Assistant Secretary General of Korean Breast Cancer Society (KBCS)

2019-present Member of Academic Program Committee and Scientific Program Committee, GBCC, KBCS

2024-present Secretary General of Korean Robot and Endoscopic Minimal Access Breast Surgery Study Group (KoREa-BSG), KBCS

2019-present Member of Protocol Development Group of Korean Breast Cancer Study Group

(KBCSG), KBCS

- 2018-present Member of Korean Clinical Practice Guideline Committee, KBCS
- 2017-present Member of Korean Hereditary Breast Cancer Study Group, KBCS
- 2024-present Academic Program Committee and Scientific Program Committee, Korean Society of Endo-Laparoscopic & Robotic Surgery (KSERS)
- 2021- present Member of Academic Program Committee and Scientific Program Committee, The Korean Association of RObotic Surgeons (KAROS)
- 2021-2023 Secretary of International Committee, KBCS
- 2019-2023 Member of International Committee, KBCS
- 2020-2021 Secretary of Academic Program Committee and Scientific Program Committee, GBCC, KBCS
- 2019-2023 Member of Educational Program Committee, KBCS
- 2019-2024 Chair of Academic Committee, KoREa-BSG, KBCS
- 2022-2024 Secretary of International Committee, Korean Society of Surgical Oncology (KSSO)
- 2022-2024 Member of Commission on Policy Planning Committee, KSSO
- 2022-2024 Secretary of International Committee, KSSO
- 2020-2022 Member of Finance Committee, KSSO
- 2022-2024 Member of Breast division of Special Committee, KSERS
- 2018-present Member, Korean Society of Surgical Oncology
- 2018-present Member, Korean Society of Lymphedema
- 2018-present Member of IRB Committee, Samsung Medical Center
- 2015-present Member, Korean Breast Cancer Society
- 2012-present Member, Korean Surgical Society

**Lectures and Presentations:**

- Nov 2025 Robot Breast Surgery: Insight of KoREa-BSG, WCES2025
- Oct 2025 Axillary management following NAC: Surgical Oncologists' point of views, TIBCS2025
- Sep 2025 Axillary Lymph Node Dissection Omission in Clinically Node-Positive Patients: SENOMAC-ULTRA, KBCS symposium 2025
- Sep 2025 The Journey of KoREa-BSG, 7<sup>th</sup> KoREa-BSG symposium
- June 2025 Updated Survival Outcomes and Predictors of Benefit from Ovarian Function Suppression in Premenopausal Women with Hormone-Receptor-Positive Breast Cancer: Results from the ASTRRA Trial (KBCSG-20), ASCO2025
- June 2025 De-escalating surgery after complete remission induced by neoadjuvant treatment, including chemotherapy, targeted therapy, and immune checkpoint inhibitors, The 3rd Current Breast Cancer Treatment Trends & Case Studies in Korea, UAE & KBCS

Apr 2025 Consensus statement on robotic mastectomy-expert panel KAROS 2025

Apr 2025 Immediate Reconstruction After Ipsilateral Breast Recurrence, GBCC2025

Apr 2025 Exploring Surgical Paths in Breast Cancer, GBCC2025

Nov 2024 Pretest Genetic Counselling and Pedigree, 14<sup>th</sup> Hereditary breast/ovarian cancer Education

Nov 2024 Robot Breast Surgery, 2024 ESSO-CACA Advanced Training Sessions of Oncoplastic and Breast Reconstruction Surgery

Oct 2024 Robot Surgery for Breast Cancer, breast cancer TV/ Meet the Master : Robot Breast Surgery (Japan)

Oct 2024 Axillary Surgery in Clinically Node Negative and Positive Disease: Current Indication, TIBCS2024

Oct 2024 De-escalation of local therapy, 25<sup>th</sup> Korean Breast Cancer Society (KBCS) Conference

Sep 2024 Robotic breast surgery practical tips and expert advice, 6<sup>th</sup> KoREa-BSG symposium, ESSO-KBCS VTB

Aug 2024 Recent trends in breast lesion localization techniques for breast cancer surgery, KBCS

May 2024 Management of the Axilla after Neoadjuvant Chemotherapy: ASLAN Trial AFSUMB2024

Apr 2024 Surgical management in young breast cancer, GBCC2024

Apr 2024 Ongoing studies of robotic mastectomy in Korea, KSERS2024

Dec 2023 Localization techniques for non-palpable breast lesions, 22<sup>th</sup> Soonchunhyang university hospital breast cancer symposium,

Nov 2023 Pretest Genetic Counselling and Pedigree, 12<sup>th</sup> Hereditary breast/ovarian cancer Education

Sep 2023 Risk reducing surgery in hereditary breast cancer, KSMO 2023

Sep 2023 Recent update and Beyond in Treatment of Early Breast Cancer, 1<sup>st</sup> Samsung Consensus Conference for early breast cancer

Sep 2023 Oncologic outcome of Nipple sparing mastectomy in BRCA1/2 mutation with breast cancer, 5<sup>th</sup> KoREa-BSG

Aug 2023 Axillary Surgery, School of breast disease, KBCS

May 2023 Update of robot breast surgery, KAROS 2023

Feb 2023 Hereditary Breast Cancer, 2023 Consensus Meeting Korean Clinical Practice Guideline Committee, Korean Breast Cancer Society

Feb 2023 Update of robot breast surgery, Seoul Asan Robot Surgery symposium 2023

Feb 2023 Optimizing strategies for breast cancer surgery, SISSO 2023

Nov 2022 Pretest Genetic Counselling and Pedigree, 12<sup>th</sup> Hereditary breast/ovarian cancer Education

Nov 2022 Paradigm change in axillary surgery, 74<sup>th</sup> annual congress of KSS

Nov 2022 Robot Assisted Nipple-Sparing Mastectomy with immediate breast reconstruction: An initial experience of Korea Robot-endoscopy Minimal access Breast Surgery study Group (KoREa-BSG01), 74<sup>th</sup> annual congress of KSS

- Oct 2022 Omitting axillary sentinel lymph node biopsy following neoadjuvant chemotherapy, 23th Korean Breast Cancer Society (KBCS) Conference
- Oct 2022 How to use ligasure in breast cancer, 18<sup>th</sup> World Congress of Endoscopic Surgery (WCES)
- Sep 2022 Update of MARRES, 4<sup>th</sup> symposium of KoREa-BSG
- June 2022 Hereditary Breast Cancer in Kore, KOHBRA study, KNUH Hereditary Cancer Symposium
- May 2022 Education program of Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) for the first case, KAROS2022
- Feb 2022 Proper management of adverse effect in immune therapy, Seoul International Symposium of Surgical Oncology (SISSO)
- Jan 2022 Robot-assisted nipple sparing mastectomy using SP system, International Robotic Surgery Live 2021
- Nov 2021 Current status of Mastectomy With Reconstruction Including Robot Endoscopic Surgery (MARRES) study, 3<sup>rd</sup> symposium of KoREa-BSG
- Nov 2021 Evolution in Oncologic safety of NSM, Plastic And Reconstructive Surgeon Korea conference 2021
- Nov 2021 Genetic Counselling in Breast Cancer Patients, 62th Conference of Korean Society of Medical Genetics and Genomics
- Oct 2021 Breast surgery using Robo, 2021 Korean Surgical Skill Study Group Conference
- Oct 2021 Breast Surgery following Neoadjuvant Treatment in HER2+ Breast Cancer, 22th Korean Breast Cancer Society Conference
- July 2021 Robotic Nipple-sparing Mastectomy With Immediate Breast Reconstruction, cross-strait seminar on the diagnosis and treatment of breast tumors 2021
- June 2021 Should we consider changing postoperative chemotherapy if preoperative chemotherapy does not meet in a complete pathological response (pCR)?, Breast Cancer Expert Young Oncologist Debate Symposium
- Apr 2021 Treatment options in *BRCA1/2* breast cancer patients, 10<sup>th</sup> Global Breast Cancer Conference
- Apr 2021 Potential Candidates for Omission of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy, 10<sup>th</sup> Global Breast Cancer Conference
- Mar 2021 Pretest Genetic Counselling and Pedigree, 11<sup>th</sup> Hereditary breast cancer Education
- Mar 2021 Hereditary Breast Cancer, 2021 Consensus Meeting Korean Clinical Practice Guideline Committee, Korean Breast Cancer Society
- Nov 2020 Robot-assisted nipple sparing mastectomy with immediate breast reconstruction, Initial experiences of Korea Robot-Endoscopy minimal access breast surgery study group (KoREa-BSG), Annual Congress of KSS 2020 & 72nd Congress of the Korean Surgical Society
- Oct 2020 Emerging treatment options for triple negative/BRCA-associate breast cancer, 경인지회

- Aug 2020 Robot-assisted nipple sparing mastectomy with immediate breast reconstruction, Initial experiences of Korea Robot-Endoscopy minimal access breast surgery study group (KoREa-BSG), KSELS 2020 & KAROS CONGRESS
- July 2020 Robot Assisted Surgery in Breast Cancer Patients, Surgical Grand Rounding at Seoul National University of Hospital
- Dec 2019 My first robot-assisted nipple sparing mastectomy, International Robotic Surgery Live 2019 (as a chair and speaker)
- Oct 2019 Pretest Genetic Counselling and Pedigree, 10<sup>th</sup> Hereditary breast cancer Education
- Oct 2019 Population based gene panel testing for primary cancer prevention, 20<sup>th</sup> Korean Breast Cancer Society Conference
- Aug 2019 Breast Surgical Management in the presence of BRCA mutations, 3<sup>rd</sup> International BRCA Forum (Singapore)
- Apr 2019 Management of Li-Fraumeni syndrome, 11<sup>th</sup> Hereditary breast cancer symposium
- Mar 2019 Hereditary Breast Cancer, 2019 Consensus Meeting Korean Clinical Practice Guideline Committee, Korean Breast Cancer Society
- June 2018 BRCA testing in TPN Breast Cancer Patients, 10<sup>th</sup> Hereditary breast cancer symposium
- Oct 2017 BRCA mutation test should be used as companion. The 3<sup>rd</sup> World Congress on Controversies in Breast Cancer (CoBrCa)
- Apr 2017 Prevalence of BRCA mutation in unselected breast cancer patients with triple negative subtype, ABRCA Consortium Business Meeting and ABRCA & HBOC session, Global Breast Cancer Conference 2017
- Oct 2016 Breast conserving surgery versus mastectomy for breast cancer patients with BRCA mutation. The 2<sup>nd</sup> Asian breast cancer conference
- Oct 2016 Oncologic safety of immediate breast reconstruction in breast cancer patients who underwent neoadjuvant chemotherapy: Short-term outcomes of a matched case control study. The 4<sup>th</sup> Congress of the Japan Oncoplastic Breast Surgery Society
- Nov 2015 Nomogram for predicting nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. The 67<sup>th</sup> Congress of the Korean Society of Surgical Society
- Sep 2015 The feasibility of nipple-sparing mastectomy with immediate breast reconstruction in breast cancer patients with tumor-nipple distance less than 2.0 cm. The 3<sup>rd</sup> Congress of the Japan Oncoplastic Breast Surgery Society

#### **Research Activities:**

#### **Publication in SCI/SCI(E) Journals – peer reviewed**

1. **Oncologic Outcome of Immediate Breast Reconstruction Following Mastectomy in Patients With Ipsilateral Breast Tumor Recurrence.** Yoo JW, Kim HJ, Shin DS, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Mun GH, Jeon BJ, Pyon JK, Lee KT, Ryu JM. *J Breast Cancer*. 2025 Oct;28(5):311-321. doi: 10.4048/jbc.2025.0053.
2. Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study. Shin E, Kim SI, Park MH, Kim HA, Jung Y, Ryu JM, Park EH, Kim SY, Lee EG, Lee MH, Park JH, Im SA, Bae SJ, Kang SH, Lim WS, Youn HJ, Park HK, Park KH, Kim TH, Park SY, Lim CW, Kwak GH, Park C, Shin HJ, Yoo YB, Kang SH, Kim BK, Kim HJ. *Front Oncol*. 2025 Oct 2;15:1465256. doi: 10.3389/fonc.2025.1465256. eCollection 2025
3. Re-evaluating the necessity of removing residual calcifications detected after surgery in HR-/HER2+ breast cancer with pathologic complete response. Lee CE, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Kim KJ, Lee SM, Lee SA, Oh K, Woen D, Kim K, Byun D, Lee J, Lee JE, Park WK. *Eur J Surg Oncol*. 2025 Sep 22;51(12):110476. doi: 10.1016/j.ejso.2025.110476. Online ahead of print..
4. Long-Term Prognostic Value and Analytical Parameters of the Next-Generation Sequencing-Based Multigene Assay in Hormone Receptor-Positive, HER2-Negative Breast Cancer. Kim H, Koh J, Lee H, Gong G, Oh S, Lee J, Chang HE, Choi Y, Kang E, Ryu JM, Shin DS, Lee SB, Lee HJ, Kim HK, Shin HC, Han W, Lee HB, Park KU. *Cancer Res Treat*. 2025 Sep 1. doi: 10.4143/crt.2025.701. Online ahead of print.
5. **The first multicenter study of robot-assisted breast-conserving surgery: insights from the KoREa-BSG group.** Choi HJ, Paek SH, Lee JH, Lee MH, Bang YJ, Kim KS, Kim HY, Park HS, Ryu JM; Korea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG). *Surg Endosc*. 2025 Sep;39(9):6222-6229. doi: 10.1007/s00464-025-11964-2. Epub 2025 Aug 11.
6. **Potential for omitting sentinel lymph node biopsy in patients with human epidermal growth factor receptor 2-positive or triple negative breast cancer with non-breast pCR after neoadjuvant chemotherapy.** Shin DS, Park J, Lee H, Park WK, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Choi HJ, Ryu JM. *Eur J Surg Oncol*. 2025 Oct;51(10):110331. doi: 10.1016/j.ejso.2025.110331. Epub 2025 Jul 15.
7. Impact of High Lymph Node Burden on Brain Metastases in Patients Who Achieved Pathological Complete Response after Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Lee SA, Kim KJ, Woen DY, Lee SM, Oh K, Lee CE, Park WK, Yoo JW, Shin DS, Ryu JM, Lee SK, Chae BJ, Yu J, Kim SW, Nam SJ, Kim JY, Park YH, Ko EY, Ko ES, Lee JE. *Cancer Res Treat*. 2025 Jul 8. doi: 10.4143/crt.2025.219. Online ahead of print.

8. Breast Cancer Information Grand Round for Survivorship (BIG-S) prospective cohort. Kang D, Park J, Kim H, Lee JE, Nam SJ, Kim SW, Yu J, Chae BJ, Ryu JM, Cho J, Lee SK. *Eur J Epidemiol*. 2025 Aug;40(8):959-968. doi: 10.1007/s10654-025-01262-5. Epub 2025 Jul 8.
9. **Consensus Statement on Robotic Nipple Sparing Mastectomy Expert Panel. Ryu JM, Mok CW, Toesca A, Lai HW, Kuo WL, Cheng FT, Song SY, Johnson J, Shin H, Park HS. *J Breast Cancer*. 2025 Jun;28(3):180-192.**
10. 17 $\beta$ -Estradiol Promotes Tumorigenicity Through an Autocrine AREG/EGFR Loop in ER- $\alpha$ -Positive Breast Cancer Cells. Yoon SY, Jeong Y, Ryu JM, Lee SK, Chae BJ, Yu J, Kim SW, Nam SJ, Kim S, Lee JE. *Cells*. 2025 May 12;14(10):703. doi: 10.3390/cells14100703.
11. **Long-Term Oncologic Outcome of Breast-Conserving Treatment in Patients With Breast Cancer With BRCA Variants. Lee J\*, Ryu JM\*, Kim HK, Park HS, Kang B, Ahn SG, Chung MS, Shin SH, Go J, Kim S, Kim EY, Kang YJ, Min SY, Lee M, Shin E, Shin J, Lee SB, Cha CD. *JAMA Netw Open*. 2025 May 1;8(5):e259840. doi: 10.1001/jamanetworkopen.2025.9840.**
12. Real-world evidence of the efficacy of neoadjuvant pembrolizumab in triple-negative breast cancer: A surgeon's point of view. Park WK, Nam SJ, Kim SW, Yu J, Lee SK, Ryu JM, Chae BJ, Shin DS, Ahn JS, Park YH, Kim JY, Shin J, Ahn HK, Cho EY, Lee H, Lee JE. *Eur J Surg Oncol*. 2025 Apr 9;51(8):110011. doi: 10.1016/j.ejso.2025.110011. Online ahead of print.
13. HER2 mRNA Score From Quantitative ERBB2 mRNA Expression of Oncotype Dx : Can It Replace the HER2 Immunohistochemistry? Lee H, Ryu JM, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Cho YA, Cho EY. *Am J Surg Pathol*. 2025 Apr 10.
14. Digital mammography with AI-based computer-aided diagnosis to predict neoadjuvant chemotherapy response in HER2-positive and triple-negative breast cancer patients: comparison with MRI. Kim H, Choi JS, Chi SA, Ryu JM, Lee JE, Kim MK, Lee J, Ko ES, Ko EY, Han BK. *Eur Radiol*. 2025 Mar 25. doi: 10.1007/s00330-025-11390-x. Online ahead of print.
15. **Prognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results. Kang E, Cheun JH, Lee J, Koh J, Lee H, Park JY, Lee HJ, Kang B, Park WK, Son J, Kim B, Chung W, Han W, Lee HB, Lee SB, Ryu JM. *Cancer Res Treat*. 2024 Dec 23. doi: 10.4143/crt.2024.1035. Online ahead of print.**
16. **Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study. Kook Y, Kim JH, Jang JS, Bae SJ, Baek SH, Jeong J, Choi JY, Shin DS, Ryu JM\*, Ahn SG\*. *Clin Breast Cancer*. 2025 Feb;25(2):164-171. doi: 10.1016/j.clbc.2024.11.006. Epub 2024 Nov 13.**
17. Pattern Analysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers. Kim D, Ryu JM, Han SA, Kim Z, Kim SW. *Curr Oncol*. 2024 Nov 1;31(11):6767-6777.

18. **Age and Late Recurrence in Young Patients With ER-Positive, ERBB2-Negative Breast Cancer.** Shin DS, Lee J, Kang E, Noh D, Cheun JH, Lee JH, Son Y, Bae SJ, Kim SW, Lee JE, Yu J, Chae BJ, Kwon S, Lee HB, Ahn SG, Ryu JM. *JAMA Netw Open*. 2024 Nov 4;7(11):e2442663. doi: 10.1001/jamanetworkopen.2024.42663.
19. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, Balbaloglu H, Balint-Lahat N, Banys-Paluchowski M, Barrio AV, Benson J, Bese N, Boughey JC, Boyle MK, Diego EJ, Eden C, Eller R, Goldschmidt M, Hlaviv C, Heidinger M, Jelinska J, Karadeniz Cakmak G, Kesmodel SB, King TA, Kuerer HM, Loesch J, Milardi F, Murawa D, Moo TA, Menes TS, Passeri D, Pastoriza JM, Perhavec A, Pislari N, Polidorio N, Rami A, Ryu JM, Schulz A, Sevilimedu V, Ugurlu MU, Uras C, van Hemert A, Wong SM, Yoo TR, Zhang JQ, Karanlik H, Cabioglu N, Peeters MV, Morrow M, Weber WP; ICARO Study Group. *J Clin Oncol*. 2024 Nov 7;JCO2401052
20. Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy. Lee YJ, Noh WC, Gwark S, Kim HA, Ryu JM, Kim SI, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Jeong J, Park E, Kim SY, Lee MH, Kim LS, Lim W, Kim S, Kim HJ. *Breast Cancer Res*. 2024 Nov 5;26(1):152. doi: 10.1186/s13058-024-01903-9.
21. Oncological outcomes in patients with residual triple-negative breast cancer after preoperative chemotherapy. Park H, Kim H, Park W, Cho WK, Kim N, Kim TG, Im YH, Ahn JS, Park YH, Kim JY, Nam SJ, Kim SW, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM. *Radiat Oncol J*. 2024 Sep;42(3):210-217. doi: 10.3857/roj.2024.00087. Epub 2024 Sep 20.
22. Nonsentinel lymph node metastases in cases of micrometastasis detected by sentinel lymph node biopsy after neoadjuvant chemotherapy. Shin DS, Ryu JM, Lee SK, Yu J, Lee JE, Kim SW, Nam SJ, Chae BJ. *Cancer*. 2024 Sep 21. doi: 10.1002/cncr.35567. Online ahead of print.
23. Evaluating the feasibility of repeat sentinel lymph node biopsy in ipsilateral breast tumor recurrence: Technical considerations and oncologic outcomes. Park WK, Kim HJ, Ryu JM, Chae BJ, Yu J, Kim SW, Nam SJ, Lee JE. *Eur J Surg Oncol*. 2024 Nov;50(11):108644.
24. **Learning curve for robot-assisted nipple-sparing mastectomy: A single institution experience.** Jung SM, Kim YJ, Lee KT, Jeon BJ, Mun GH, Pyon JK, Ryu JM. *Eur J Surg Oncol*. 2024 Oct;50(10):108602.
25. **Minimal Access vs Conventional Nipple-Sparing Mastectomy.** Kim JH\*, Ryu JM\*, Bae SJ, Ko BS, Choi JE, Kim KS, Cha C, Choi YJ, Lee HY, Nam SE, Kim Z, Kang YJ, Lee MH, Lee JE, Park E, Shin HJ, Kim MK, Choi HJ, Kwon SU, Son NH, Park HS, Lee J; Korea Robot-endoscopy Minimal Access Breast Surgery Study Group. *JAMA Surg*. 2024 Oct 1;159(10):1177-1186. doi: 10.1001/jamasurg.2024.2977.

26. The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer. Park WK, Nam SJ, Kim SW, Lee JE, Yu J, Lee SK, Ryu JM, Chae BJ. *Cancers (Basel)*. 2024 Jul 17;16(14):2566. doi: 10.3390/cancers16142566.
27. Endoxifen Concentration is Associated with Recurrence-Free Survival in Hormone-Sensitive Breast Cancer Patients. Lee B, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Lee JE, Lee SY. *Cancer Res Treat*. 2024 Jun 18. doi: 10.4143/crt.2023.1285. Online ahead of print.
- 28. The Effects of National Insurance Coverage Expansion and Genetic Counseling's Role on BRCA1/2 Mutation Tests in Breast Cancer Patients. Jang SY, Kwak Y, Choi JY, Shin DS, Lee H, Kim M, Jung BY, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. *Cancers (Basel)*. 2024 May 14;16(10):1865. doi: 10.3390/cancers16101865.**
29. Current practices and challenges in genetic testing and counseling for women with breast and ovarian cancer in Asia. Kwong A, Tan DS, Ryu JM; ACROSS Consortium. *Asia Pac J Clin Oncol*. 2024 May 22. doi: 10.1111/ajco.14074. Online ahead of print.
- 30. Long-term oncologic outcomes of unselected triple-negative breast cancer patients according to BRCA1/2 mutations. Park WK, Chung SY, Jung YJ, Ha C, Kim JW, Nam SJ, Kim SW, Yu J, Chae BJ, Lee JE, Kim SW, Ryu JM; Korean Hereditary Breast Cancer Study Group. *NPJ Precis Oncol*. 2024 Apr 30;8(1):96. doi: 10.1038/s41698-024-00559-0.**
- 31. Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response. Ryu JM, Lee H, Han W, Lee HB, Ahn SG, Kim HJ, Park HS, Choi JS, Kim H, Cho WK, Lee JE. *J Breast Cancer*. 2024 Apr;27(2):130-140. doi: 10.4048/jbc.2023.0264.**
32. Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a scoping review. Afaya A, Kim SW, Park HS, Lim MC, Jung MS, Nam EJ, Park JS, Jeong J, Ryu JM, Kim J, Kim J, Kim M, Jin J, Han J, Kim SY, Park SY, Katapodi MC, Kim S; K-CASCADE consortium. *Fam Cancer*. 2024 Jun;23(2):121-132. doi: 10.1007/s10689-024-00379-y. Epub 2024 Apr 25.
33. Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1-3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study. Bae SJ, Chun JW, Lee SB, Ryu JM, Nam SJ, Jeong J, Park HS, Ahn SG. *Breast Cancer Res*. 2024 Apr 17;26(1):66. doi: 10.1186/s13058-024-01807-8.
34. Impact of residual microcalcifications on prognosis after neoadjuvant chemotherapy in breast cancer patients. Kim EY, Lee KH, Yun JS, Park YL, Park CH, Jang SY, Ryu JM, Lee SK, Chae BJ, Lee JE, Kim SW, Nam SJ, Yu JH. *BMC Womens Health*. 2024 Mar 20;24(1):187. doi: 10.1186/s12905-024-02973-9.
35. Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant

- Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial. Jung JJ, Cheun JH, Kim SY, Koh J, Ryu JM, Yoo TK, Shin HC, Ahn SG, Park S, Lim W, Nam SE, Park MH, Kim KS, Kang T, Lee J, Youn HJ, Kim YS, Yoon CI, Kim HK, Moon HG, Han W, Cho N, Kim MK, Lee HB. *J Breast Cancer*. 2024 May;31(3):391-400.
36. Outcomes of whole breast radiation therapy in Asian breast cancer patients with prior cosmetic implants. Kim N, Cho WK, Park W, Lee JE, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Ko ES, Kim H. *Breast Cancer*. 2024 Feb 18. doi: 10.1007/s12282-024-01547-9.
- 37. Oncologic Outcomes of Immediate Breast Reconstruction in the Setting of Neoadjuvant Chemotherapy: A Long-term Follow-up Study of a Matched Cohort. Shin DS, Bang YJ, Choi JY, Jang SY, Lee H, Kwak Y, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Jeon BJ, Pyon JK, Mun GH, Lee KT, Ryu JM. *J Breast Cancer*. 2024 Feb;27(1):14-26.**
38. The Role of Post-Mastectomy Radiotherapy in T1-2N1 Breast Cancer Patients: Propensity Score Matched Analysis. Kim K, Park W, Kim H, Cho WK, Kim N, Nam SJ, Kim SW, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM. *Cancers (Basel)*. 2023 Nov 19;15(22):5473.
39. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study. Bae SJ, Kim HJ, Kim HA, Ryu JM, Park S, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Park E, Kim SY, Lee MH, Kim LS, Lee A, Noh WC, Gwark S, Kim S, Jeong J. *Int J Surg*. 2024 Feb 1;110(2):934-942.
40. The Impact of HER2-Low Expression on Oncologic Outcomes in Hormone Receptor-Positive Breast Cancer. Park WK, Nam SJ, Kim SW, Lee JE, Yu J, Ryu JM, Chae BJ. *Cancers (Basel)*. 2023 Nov 10;15(22):5361. doi: 10.3390/cancers15225361.
41. Survival Outcomes in Premenopausal Patients With Invasive Lobular Carcinoma. Yoon TI, Jeong J, Lee S, Ryu JM, Lee YJ, Lee JY, Hwang KT, Kim H, Kim S, Lee SB, Ko BS, Lee JW, Son BH, Metzger O, Kim HJ. *JAMA Netw Open*. 2023 Nov 1;6(11):e2342270. doi: 10.1001/jamanetworkopen.2023.42270. PMID: 37938845
42. Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer. Kim N, Kim JY, Park W, Cho WK, Kim TG, Im YH, Ahn JS, Lee JE, Nam SJ, Kim SW, Yu J, Chae BJ, Lee SK, Ryu JM, Park YH, Kim H. *Breast*. 2023 Oct 30;72:103594. doi: 10.1016/j.breast.2023.103594. Online ahead of print.
- 43. Risk factors of breast cancer recurrence in pathologic complete response achieved by patients following neoadjuvant chemotherapy: a single-center retrospective study JY Choi, D Woen, SY Jang, Hyunjun Lee, DS Shin, Y Kwak, H Lee, BJ Chae, J Yu, JE Lee, SW Kim, SJ Nam, JM Ryu *Front Oncol*. 2023 Oct 2;13:1230310.**
44. Acceptability and Usability of the Family Gene Toolkit for Swiss and Korean Families Harboring

- BRCA1/BRAC2 Pathogenic Variants: A Web-Based Platform for Cascade Genetic Testing. Baroutsou V, Duong V, Signorini A, Saccilotto R, Ciorba FM, Bürki N, Caiata-Zufferey M, Ryu JM, Kim SW, Lim MC, Monnerat C, Zürcher-Härdi U, Kim J, Heinemann K, Graffeo R, Park JS, Rabaglio M, Chappuis PO, Kim S, Katapodi MC, On Behalf Of The Cascade And K-Cascade Consortia. *Cancers (Basel)*. 2023 Sep 9;15(18):4485.
45. Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial. Baek SY, Noh WC, Ahn SH, Kim HA, Ryu JM, Kim SI, Lee EG, Im SA, Jung Y, Park MH, Park KH, Kang SH, Jeong J, Park E, Kim SY, Lee MH, Kim LS, Lim W, Kim S, Kim HJ. *J Clin Oncol*. 2023 Aug 22
46. **Progesterone Receptor Expression Level Predicts Prognosis of Estrogen Receptor-Positive/HER2-Negative Young Breast Cancer: A Single-Center Prospective Cohort Study.** Kwak Y, Jang SY, Choi JY, Lee H, Shin DS, Park YH, Kim JY, Ahn JS, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. *Cancers (Basel)*. 2023 Jun 30;15(13):3435.
47. Trends of axillary surgery in breast cancer patients with axillary lymph node metastasis: a comprehensive single-center retrospective study. Kim YJ, Kim HJ, Chung SY, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. *Ann Surg Treat Res*. 2023 Jul;105(1):10-19.
48. **Mastectomy with Reconstruction Including Robotic Endoscopic Surgery (MARRES): a prospective cohort study of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG) and Korean Breast Cancer Study Group (KBCSG).** Ryu JM, Lee J, Lee J, Ko B, Kim JH, Shin H, Park HS; Korea Robot-endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG). *BMC Cancer*. 2023 Jun 21;23(1):571.
49. Prediction Model for Postoperative Quality of Life Among Breast Cancer Survivors Along the Survivorship Trajectory From Pretreatment to 5 Years: Machine Learning-Based Analysis. Kang D, Kim H, Cho J, Kim Z, Chung M, Lee JE, Nam SJ, Kim SW, Yu J, Chae BJ, Ryu JM, Lee SK. *JMIR Public Health Surveill*. 2023 Aug 24;9:e45212.
50. Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA. Bae M, Kim G, Lee TR, Ahn JM, Park H, Park SR, Song KB, Jun E, Oh D, Lee JW, Park YS, Song KW, Byeon JS, Kim BH, Sohn JH, Kim MH, Kim GM, Chie EK, Kang HC, Kong SY, Woo SM, Lee JE, Ryu JM, Lee J, Kim D, Ki CS, Cho EH, Choi JK. *Nat Commun*. 2023 Apr 10;14(1):2017.
51. **Prognostic Impact of Elevation of Cancer Antigen 15-3 (CA15-3) in Patients With Early Breast Cancer With Normal Serum CA15-3 Level.** Ryu JM, Kang D, Cho J, Lee JE, Kim SW, Nam SJ, Lee SK, Kim YJ, Im YH, Ahn JS, Park YH, Kim JY, Lee H, Kang M, Yu JH. *J Breast Cancer*. 2023 Apr;26(2):126-135.
52. Impact of Adjuvant Hormone Therapy on Sleep, Physical Activity, and Quality of Life in

- Pre-menopausal Breast Cancer: 12-Month Observational Study. Yeo SM, Lim JY, Kim SW, Chae BJ, Yu J, Ryu JM, Hwang JH. *J Breast Cancer*. 2023 Apr;26(2):93-104.
53. Integrative modeling of tumor genomes and epigenomes for enhanced cancer diagnosis by cell-free DNA. Bae M, Kim G, Lee TR, Ahn JM, Park H, Park SR, Song KB, Jun E, Oh D, Lee JW, Park YS, Song KW, Byeon JS, Kim BH, Sohn JH, Kim MH, Kim GM, Chie EK, Kang HC, Kong SY, Woo SM, Lee JE, Ryu JM, Lee J, Kim D, Ki CS, Cho EH, Choi JK. *Nat Commun*. 2023 Apr 10;14(1):2017.
54. The efficacy and safety of an indocyanine green-hyaluronic acid mixture (LuminoMark™) for localization in patients with non-palpable breast lesions: A multicenter, randomized, open-label, parallel phase 3 clinical trial. Bang YJ, Choi HJ, Kim I, Lee MH, Lee S, Shin HJ, Nam SJ, Lee JE, Chae BJ, Lee SK, Ryu JM, Kim SW. *Front Oncol*. 2023 Mar 24;13:1039670.
55. The use of absorbable skin stapler in mastectomy does not increase the rate of surgical site infection. Lee J, Lee JE, Ryu JM, Kim SW, Nam SJ, Yu JH. *Ann Surg Treat Res*. 2023 Mar;104(3):137-143.
56. Clinical Characteristics and Prognosis of Metaplastic Breast Cancer Compared with Invasive Ductal Carcinoma: A Propensity-Matched Analysis. Lee JH, Ryu JM, Lee SK, Chae BJ, Lee JE, Kim SW, Nam SJ, Yu J. *Cancers (Basel)*. 2023 Mar 2;15(5):1556.
57. Robot-assisted mastectomy: next major advance in breast cancer surgery. Toesca A, Park HS, Ryu JM, Kim YJ, Lee J, Sangalli C, Maisonneuve P, Marrazzo E, Pozzi G, Gazzetta G, Montemurro F, Corso G, Lissidini G, Caldarella P, Mazzotta E, Massari G, Veronesi P. *Br J Surg*. 2023 Jan 27: Online ahead of print.
- 58. Comprehensive clinical characterization of patients with BRCA1: c.5017\_5019del germline variant. Bang YJ, Kwon WK, Kim JW, Lee JE, Jung BY, Kim M, Kim J, An J, Jung SP, Kim HK, Kim Z, Youn HJ, Ryu JM, Kim SW; Korean Hereditary Breast Cancer Study Group. *Ann Surg Treat Res*. 2022 Dec;103(6):323-330.**
- 59. Association of Fat Graft with Breast Cancer Recurrence in Implant-Based Reconstruction: Does the Timing Matter? Lee KT, Kim JH, Jeon BJ, Pyon JK, Mun GH, Lee SK, Yu J, Kim SW, Lee JE, Ryu JM, Bang SI. *Ann Surg Oncol*. 2023 Feb;30(2):1087-1097.**
- 60. Predicting the Response of Neoadjuvant Chemotherapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer With Axillary Lymph Node Metastasis by Multigene Assay. Lee JH, Ryu JM, Ahn JH, Cho SY, Lee SK, Yu J, Chae BJ, Nam SJ, Han J, Lee JE, Kim SW. *J Breast Cancer*. 2022 Dec;25(6):473-484.**
61. Is Pathologic Axillary Staging Valid If Lymph Nodes Are Less than 10 with Axillary Lymph Node Dissection after Neoadjuvant Chemotherapy? Choi HJ, Ryu JM, Lee JH, Bang Y, Oh J, Chae BJ, Nam SJ, Kim SW, Lee JE, Lee SK, Yu J. *J Clin Med*. 2022 Nov 5;11(21):6564.
62. Long-Term Breast Cancer Outcomes of Pregnancy-Associated Breast Cancer (PABC) in a

- Prospective Cohort. Jo H, Park S, Kim HR, Kim H, Hong J, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM, Oh SY, Choi SJ, Kim JY, Ahn JS, Im YH, Nam EM, Nam SJ, Park YH. *Cancers (Basel)*. 2022 Oct 4;14(19):4839.
63. Suggestion for the omission of post-mastectomy chest wall radiation therapy in patients who underwent skin-sparing/nipple-sparing mastectomy. Kim N, Park W, Cho WK, Kim HY, Choi DH, Nam SJ, Kim SW, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM, Mun GH, Pyon JK, Jeon BJ. *Breast*. 2022 Dec;66:54-61
64. Comparison of Recurrence Rate Between Re-Excision With Radiotherapy and Radiotherapy-Only Groups in Surgical Margin Involvement of In Situ Carcinoma. Lee JH, Lee H, Bang YJ, Ryu JM, Lee SK, Yu J, Lee JE, Kim SW, Nam SJ, Chae BJ. *J Breast Cancer*. 2022 Aug;25(4):288-295.
65. Impact of the ACOSOG Z0011 trial on surgical practice in Asian patients: trends in axillary surgery for breast cancer from a Korean Breast Cancer Registry analysis. Cha C, Kim EY, Kim SY, Ryu JM, Park MH, Lee S, Suh YJ, Choi N, Hong H, Kim HS, Chung MS; Korean Breast Cancer Society. *World J Surg Oncol*. 2022 Jun 13;20(1):198.
66. Discovery of BRCA1/BRCA2 founder variants by haplotype analysis. Kwon WK, Jang HJ, Lee JE, Park YH, Ryu JM, Yu J, Jang JH, Kim JW. *Cancer Genet*. 2022 Aug;266-267:19-27.
67. Primary Angiosarcoma of the Breast: A Single-Center Retrospective Study in Korea. Kim YJ, Ryu JM, Lee SK, Chae BJ, Kim SW, Nam SJ, Yu JH, Lee JE. *Curr Oncol*. 2022 May 4;29(5):3272-3281.
68. Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis. Park HS, Lee J, Lai HW, Park JM, Ryu JM, Lee JE, Kim JY, Marrazzo E, De Scalzi AM, Corso G, Montemurro F, Gazzetta G, Pozzi G, Toesca A. *Ann Surg Oncol*. 2022 Oct;29(11):6646-6657.
- 69. Relationship Between Breast and Axillary Pathologic Complete Response According to Clinical Nodal Stage: A Nationwide Study From Korean Breast Cancer Society. Ryu JM, Choi HJ, Park EH, Kim JY, Lee YJ, Park S, Lee J, Park HK, Nam SJ, Kim SW, Lee JH, Lee JE; Korean Breast Cancer Society. *J Breast Cancer*. 2022 Apr;25(2):94-105.**
70. No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial. Jung JG, Ahn SH, Lee S, Kim EK, Ryu JM, Park S, Lim W, Jung YS, Chung IY, Jeong J, Chang JH, Shin KH, Chang JM, Moon WK, Han W. *BMC Cancer*. 2022 Feb 20;22(1):189. doi: 10.1186/s12885-022-09273-1.
71. Real World Evidence of Neoadjuvant Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Kim JY, Nam SJ, Lee JE, Yu J, Chae BJ, Lee SK, Ryu JM, Ahn JS, Im YH, Kim SW, Park YH. *Cancer Res Treat*. 2022 Oct;54(4):1091-1098.
72. From cadaveric and animal studies to the clinical reality of robotic mastectomy: a feasibility report

- of training program., Lee J, Park HS, Lee DW, Song SY, Yu, J, Ryu JM, Bae SJ, Lew DH, Kim SI, Toesca, A. *Sci Rep* 11(1): 21032.
73. Is Sentinel Lymph Node Biopsy for Breast Cancer with Cytology-Proven Axillary Metastasis Safe? A Prospective Single-Arm Study. Choi, HJ, Ryu JM, Chae BJ, Nam SJ, Yu J, Lee SK, Lee JE, Kim SW. *J Clin Med* 2021 Oct 16;10(20):4754.
  74. Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors. Shim S, Kang D, Kin N, Han G, Lim J, Kim H, Park, J, Lee M, Lee JE, Kim SW, Yu J, Chae BJ, Ryu JM, Nam SJ, Lee SK, Cho J. *Cancer Res Treat.*2022 Jul;54(3):834-841.
  75. Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. Bang, YJ, Kwon WK, Nam SJ, Kim SW, Chae BJ, Lee SK, Ryu JM, Kim JW, Yu J, Lee JE. *Cancer Res Treat* 2022 Jul;54(3):827-833
  76. Comparison of clinicopathological characteristics and prognosis in breast cancer patients with different Breast Imaging Reporting and Data System categories. Kim, B. K., Ryu JM et al. *Annals of Surgical Treatment and Research* 2021 Sep; 101(3): 131-139
  77. Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients. Cho SY, Lee JH, Ryu JM, Lee JE, Cho EY, Ahn CH, Paeng K, Yoo I, Ock CY, Song SY. *Sci Rep.* 2021 Aug 30;11(1):17363.
  - 78. Effect of Poloxamer-Based Thermo-Sensitive Sol-Gel Agent on Upper Limb Dysfunction after Axillary Lymph Node Dissection: A Double-Blind Randomized Clinical Trial. Choi HJ, Ryu JM, Chae BJ, Kim EK, Min JW, Shin HJ, Nam SJ, Yu J, Lee JE, Lee SK, Kim SW. *J Breast Cancer.* 2021 Aug;24(4):367-376.**
  - 79. Changes in Korean National Healthcare Insurance Policy and Breast Cancer Surgery Trend in Korea. Rayzah M, Ryu JM, Lee JH, Nam SJ, Kim SW, Lee SK, Yu J, Lee KT, Bang SI, Mun GH, Pyon JK, Jeon BJ, Lee JE. *J Korean Med Sci.* 2021 Jul 26;36(29):e194**
  - 80. Preoperative diagnosis of BRCA1/2 mutation impacts decision-making for risk-reducing mastectomy in breast cancer patients. Woo J, Gwak G, Park I, Bae BN, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. *Sci Rep.* 2021 Jul 20;11(1):14747.**
  - 81. Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea. Lee JH, Lee SK, Chae BJ, Yu J, Lee JE, Kim SW, Nam SJ, Ryu JM. *Front Oncol.* 2021 Jun 21;11:691277.**
  82. Using a Tailored Digital Health Intervention for Family Communication and Cascade Genetic Testing in Swiss and Korean Families With Hereditary Breast and Ovarian Cancer: Protocol for the DIALOGUE Study. Kim S, Aceti M, Baroutsou V, Bürki N, Caiata-Zufferey M, Cattaneo M, Chappuis PO, Ciorba FM, Graffeo-Galbiati R, Heinzelmann-Schwarz V, Jeong J, Jung MM, Kim SW, Kim J, Lim MC, Ming C, Monnerat C, Park HS, Park SH, Pedrazzani CA, Rabaglio M, Ryu

- JM, Saccilotto R, Wieser S, Zürrer-Härdi U, Katapodi MC. JMIR Res Protoc. 2021 Jun 11;10(6):e26264. doi: 10.2196/26264.
83. Clinical Features of Breast Cancer in South Korean Patients with Germline TP53 Gene Mutations. Alyami H, Yoo TK, Cheun JH, Lee HB, Jung SM, Ryu JM, Bae SJ, Jeong J, Yoon CI, Ahn J, Paik PS, Cho MK, Park WC. J Breast Cancer. 2021 Apr;24(2):175-182.
84. The efficacy and safety of indocyanine green-hyaluronic acid mixture (LuminoMark) for localization in patients with non-palpable breast lesions: a multi-center open-label parallel phase-2 clinical trial. Kim I, Choi HJ, Ryu JM, Lee SK, Yu JH, Lee JE, Nam SJ, Shin HJ, Kim SW. BMC Surg. 2021 Mar 16;21(1):134.
85. **Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2- Early Breast Cancer. Kwon MJ\*, Ryu JM\*, Cho SY, Nam SJ, Kim SW, Lee J, Lee SJ, Park JY, Park HY, Hong S, Kim K, Han J, Moon Y, Shin YK, Lee JE. Front Oncol. 2021 Feb 23;11:588728.**
86. Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. Min SK, Lee SK, Woo J, Jung SM, Ryu JM, Yu J, Lee JE, Kim SW, Chae BJ, Nam SJ. J Breast Cancer. 2021 Feb;24(1):75-84. doi: 10.4048/jbc.2021.24.
87. Does chemotherapy or radiotherapy affect the postoperative complication in breast cancer patients who underwent immediate breast reconstruction with tissue expander? Jung SM, Jeon BJ, Woo J, Ryu JM, Lee SK, Chae BJ, Yu J, Kim SW, Nam SJ, Pyon JK, Mun GH, Bang SI, Lee JE. BMC Cancer. 2021 Jan 22;21(1):88.
88. **Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation. SM Jung,\* JM Ryu,\* HS Park, JS Park, E Kang, S Lee, HB Lee, HJ Youn, TK Yoo, J Kim, JE Lee, SA Han, D Kim, SW Kim, and Korean Hereditary Breast Cancer Study Group J Breast Cancer. 2020 Dec;23(6):647-655.**
89. **Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. Woo J\*, Ryu JM\*, Jung SM, Choi HJ, Lee SK, Yu J, Lee JE, Kim SW, Nam SJ, Chae BJ. Eur J Surg Oncol. 2021 Feb;47(2):232-239.**
90. Is the intraoperative frozen section analysis of sentinel lymph nodes necessary in clinically negative node breast cancer? Jung SM, Woo Jinsun, Ryu JM, Lee SK, Chae BJ, Yu J, Kim SW, Nam SJ, Kim EJ, Lee JE Ann Surg Treat Res. 2020 Nov;99(5):251-258
91. Association of the Implant Surface Texture Used in Reconstruction With Breast Cancer Recurrence. Lee KT, Kim S, Jeon BJ, Pyon JK, Mun GH, Ryu JM, Lee SK, Yu J, Kim SW, Lee JE, Nam SJ, Bang SI. JAMA Surg. 2020 Dec 1;155(12):1132-1140.
92. Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women. Park JW, Han K, Shin DW, Yeo Y, Chang JW, Yoo JE, Jeong SM, Lee SK, Ryu JM, Park YM. Breast Cancer Res Treat. 2021 Jan;185(2):495-506.

93. Serum Vitamin Levels and Their Relationships with Other Biomarkers in Korean Breast Cancer Patients. Kim JA, Choi R, Won H, Kim S, Choi HJ, Ryu JM, Lee SK, Yu J, Kim SW, Lee JE, Lee SY. *Nutrients*. 2020 Sep 16;12(9):E2831
94. Robot-assisted Nipple-sparing Mastectomy with Immediate Breast Reconstruction: An Initial Experience of the Korea Robot-Endoscopy Minimal Access Breast Surgery Study Group (KoREa-BSG). Ryu JM, Kim JY, Choi HJ, Ko BS, Kim J, Cho J, Lee MH, Choi JE, Kim JH, Lee J, Jung SM, Shin HJ, Lee J, Park HS. *Ann Surg*. 2022 May 1;275(5):985-991
95. Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant. Park HS, Ryu JM\* et al. *Cancer Res Treat*. 2020 Jul;52(3):680-688
96. Aberrant Lymphatic Drainage in the Contralateral Axilla in Patients with Isolated Ipsilateral Breast Tumor Recurrence. Ryu JM, Chae BJ, Lee JE, Yu J, Nam SJ, Kim SW, Lee SK. *J Clin Med*. 2020 Apr 22;9(4):1192.
97. Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors. Ryu JM et al. *Jpn J Clin Oncol*. 2020 Feb 17;50(2):104-113
98. Oncologic Outcomes of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Patients with Tumor-Nipple Distance Less than 2.0 cm. Alsharif E\*, Ryu JM\* et al. *J Breast Cancer*. 2019 Oct 7;22(4):613-623
99. Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Choi HJ\*, Ryu JM\*, Kim I, Lee SK, Yu J, Kim JE, Kang BI, Lee JE, Nam SJ, Kim SW *Breast Cancer Res Treat*. 2019 Aug;176(3):591-596
100. Nomogram for accurate prediction of breast and axillary pathologic response after neoadjuvant chemotherapy in node positive patients with breast cancer. Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J, Lee JE, Lee SK. *Ann Surg Treat Res*. 2019 Apr;96(4):169-176
101. Only estrogen receptor "positive" is not enough to predict the prognosis of breast cancer. Ryu JM, Choi HJ, Kim I, Lee SK, Yu J, Kim JE, Kang BI, Lee JE, Nam SJ, Kim SW. *Breast Cancer Res Treat*. 2018 Dec;172(3):627-636
102. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea. Ryu JM, Choi HJ, Kim I, Nam SJ, Kim SW, Yu J, Lee SK, Choi DH, Park YH, Kim JW, Seo JS, Park JH, Lee JE, Kim SW; Korean Hereditary Breast Cancer Study Group *Breast Cancer Res Treat*. 2019 Jan;173(2):385-395
103. A predictive model for high/low risk group according to oncotype DX recurrence score using machine learning. Kim I, Choi HJ, Ryu JM, Lee SK, Yu JH, Kim SW, Nam SJ, Lee JE. *Eur J Surg Oncol*. 2019 Feb;45(2):134-140
104. Serum Trace Elements and Their Associations with Breast Cancer Subgroups in Korean Breast Cancer Patients. Choi R, Kim MJ, Sohn I, Kim S, Kim I, Ryu JM, Choi HJ, Kim JM, Lee SK, Yu

- J, Kim SW, Nam SJ, Lee JE, Lee SY *Nutrients*. 2018 Dec 24;11(1).
105. Use of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Patients with Axillary Node-Positive Breast Cancer in Diagnosis. Choi HJ, Kim I, Alsharif E, Park S, Kim JM, Ryu JM, Nam SJ, Kim SW, Yu J, Lee SK, Lee JE. *J Breast Cancer*. 2018 Dec;21(4):433-441
106. Patterns of Axillary Lymph Node Metastasis in Breast Cancer: A Prospective Single-Center Study. Choi HJ, Kim JM, Ryu JM, Kim I, Nam SJ, Yu J, Lee SK, Lee JE, Kim SW. *J Breast Cancer*. 2018 Dec;21(4):447-452
107. Risk Factors Affecting Breast Cancer-related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane. Park S, Lee JE, Yu J, Paik HJ, Ryu JM, Kim I, Bae SY, Lee SK, Kim SW, Nam SJ, Kim EK, Kang E, Yang EJ *Clin Breast Cancer*. 2017 Jun 21 Epub ahead of print
108. Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer. Park S, Lee SK, Paik HJ, Ryu JM, Kim I, Bae SY, Yu J, Kim SW, Lee JE, Nam SJ. *Medicine (Baltimore)*. 2017 Jun;96(22):e6777
109. Comparison of Core Needle Biopsy and Surgical Specimens in Determining Intrinsic Biological Subtypes of Breast Cancer with Immunohistochemistry. You K, Park S, Ryu JM, Kim I, Lee SK, Yu J, Kim SW, Nam SJ, Lee JE. *J Breast Cancer*. 2017 Sep;20(3):297-303
110. Development of a Nomogram to Predict N2 or N3 Stage in T1-2 Invasive Breast Cancer Patients with No Palpable Lymphadenopathy. Kim I, Ryu JM, Kim JM, Choi HJ, Lee SK, Yu JH, Lee JE, Kim SW, Nam SJ. *J Breast Cancer*. 2017 Sep; 20(3):270-278.
111. Genetic Diagnosis before Surgery has an Impact on Surgical Decision in BRCA Mutation Carriers with Breast Cancer. Park S, Lee JE, Ryu JM, Kim I, Bae SY, Lee SK, Yu J, Kim SW, Nam SJ. *World J Surg*. 2018 May; 42(5):1384-1390.
112. Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer. Kim I, Choi HJ, Ryu JM, Lee SK, Yu JH, Kim SW, Nam SJ, Lee JE. *J Breast Cancer*. 2018 Jun;21(2):173-181
113. Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer. Kim JM, Ryu JM, Kim I, Choi HJ, Nam SJ, Kim SW, Yu J, Lee SK, Lee JE. *J Breast Cancer*. 2018 Jun;21(2):222-226
- 114. Predictive factors for nonsentinel lymph node metastasis in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy. Ryu JM, SK Lee\*, JY Kim, HJ Paik, S Park, J Yu, SW Kim, JE Lee, SY, Bae, SW Han, YS Jung, SJ Nam. *Clin Breast Cancer*. 2017 Nov;17(7):550-558.**
- 115. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society. Ryu JM, Yu J, Kim SI,**

- Kim KS, Moon HG, Choi JE, Jeong J, Do Byun K, Nam SJ, Lee JE, Lee SK, Kim SW. *Breast Cancer Res Treat.* 2017 Dec;166(3):833-842
116. **Suggestion of BRCA1 c.5339T>C (p.L1780P) variant confer from 'unknown significance' to 'Likely pathogenic' based on clinical evidence in Korea.** Ryu JM, Kang G, Nam SJ, Kim SW, Yu J, Lee SK, Bae SY, Park S, Paik HJ, Kim JW, Park SS, Lee JE, Kim SW. *Breast.* 2017 Jun;33:109-116
117. **Oncologic Outcomes after Immediate Breast Reconstruction Following Total Mastectomy in Patients with Breast Cancer: A Matched Case-Control Study.** Ryu JM, Paik HJ, Park S, Yi HW, Nam SJ, Kim SW, Lee SK, Yu J, Bae SY, Lee JE. *J Breast Cancer.* 2017 Mar;20(1):74-81
118. Conditional disease-free survival among patients with breast cancer. Paik HJ, Lee SK, Ryu JM, Park S, Kim I, Bae SY, Yu J, Lee JE, Kim SW, Nam SJ. *Medicine (Baltimore).* 2017 Jan;96(1):e5746
119. Fertility Rates in Young Korean Breast Cancer Patients Treated with Gonadotropin-Releasing Hormone and Chemotherapy. Kim I, Ryu JM, Paik HJ, Park S, Bae SY, Lee SK, Yu J, Kim SW, Nam SJ, Lee JE. *J Breast Cancer.* 2017 Mar;20(1):91-97.
120. **Breast cancer-specific mortality in small-sized tumor with node-positive breast cancer: a nation-wide study in Korean breast cancer society.** Ryu JM, HJ Lee, TI Yoon, ES Lee, SJ Lee, JH Jung, BJ Chae, SJ Nam, JE Lee, SK Lee, SY Bae, J Yu, SW Kim, Korean Breast Cancer Society Consortium. *Breast Cancer Res Treat* 2016 Oct 159(3):489–498
121. **Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.** Alramadhan M\*, Ryu JM\*, Rayzah M, Nam SJ, Kim SW, Yu J, Lee SK, Bae SY, Park S, Paik HJ, Lee JE. *Breast.* 2016 Dec;30:111-117
122. **Oncologic safety of immediate breast reconstruction in breast cancer patients who underwent neoadjuvant chemotherapy: Short-term outcomes of a matched case control study.** JM Ryu, S Park, HJ Paik, SJ Nam, SW Kim, SK Lee, J Yu, SY Bae, I Kim, SI Bang, GH Mun, JK Pyon, BJ Jeon\*, JE Lee\* *Clin Breast Cancer.* 2017 Jun;17(3):204-210
123. Independent Prognostic Factors for Overall Survival after Salvage Operation for Ipsilateral Breast Tumor Recurrence Following Breast-Conserving Surgery. Lee JH, Lee SK, Park SM, Ryu JM, Paik HJ, Yi HW, Bae SY, Lee JE, Kim SW, Nam SJ. *J Breast Cancer.* 2015 Dec;18(4):386-93.
124. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer. Park SM, Lee JE, Paik HJ, Ryu JM, Bae SY, Lee SK, Kim SW, Nam SJ. *Clin Breast Cancer.* 2017 Feb;17(1):e19-e29.
125. **Feasibility of Nipple-Sparing Mastectomy with Immediate Breast Reconstruction in Breast Cancer Patients with Tumor-Nipple Distance Less Than 2.0 cm.** Ryu JM, Nam SJ,

Kim SW, Lee SK, Bae SY, Yi HW, Park S, Paik HJ, Lee JE. World J Surg. 2016 Aug; 40(8):2028-35, 2028–2035

**Publication in non-SCI Journals– peer reviewed**

1. **Trends in Operation Times for Robot-assisted Nipple-sparing Mastectomy Performed by Expert Breast Surgeons JH Kim\* SB Lee\* HS Park, KS Kim, JE Choi, MH Lee, J Lee, YW Chang, SH Paek, SY Min, JY You, C Cha, YY Kim, HJ Choi, ES Lee, JM Ryu,1† and YJ Kang,† Ann Robot Innov Surg. 2024 May;5(1):1-9.**
2. **Prognostic Factors for Premenopausal Women with Distant Metastatic Breast Cancer, Seung J, Ryu JM, Nam SJ, Lee JE, Yu J, Lee SK, Chae BJ, Kim SW Journal of Breast Disease 2020; 8(1): 1-8.**
3. **Necessity of In Situ Hybridization Test of Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Patients with Equivocal HER2 Immunohistochemistry Results. HJ Paik, HJ Choi, JM RYU, S Park, I Kim, SK Lee, J Yu, SW Kim, SJ Nam, JE Lee J Breast Dis. 2018;6(1):1-10**
4. **Comparison of Prognosis according to Tumor Size in Small Breast Cancer with Lymph Node Involvement HS Han, JM Ryu, I Kim, HJ Paik, S Park, SY Bae, SK Lee, J Yu, JE Lee, SJ Nam, SW Kim Journal of Breast Disease 2016; 4(2): 48-57.**
5. **Preoperative Breast Magnetic Resonance Imaging for the Assessment of the Size of Ductal Carcinoma In Situ. Rayzah M, JM Ryu, JE Lee, Mansour Alramadhan, B Han, HW Yi, S Park, HJ Paik, SJ Nam Journal of Breast Disease 2016; 4(2): 77-84.**
6. **Postoperative Outcomes in Patients Undergoing Adrenalectomy for Primary Aldosteronism. JM Ryu, SP Jung, JH Lee, JY Kim, MY Choi, SK Lee, WH Kil, JH Choe, JE Lee, JS Kim, SJ Nam, JH Yang, JH Kim Korean J Endocr Surg 2011 Dec; 11(4): 276~282**

Sign:

Last Updated: 2025-11-14